Precision BioSciences Announces Formation of Scientific Advisory Board With Anderson, Kantarjian, Schinazi and Turtle

From Startup Precision Biosciences Link to Full Article: DURHAM, North Carolina, USA, January 16, 2019 – Precision BioSciences today announced the formation of its Scientific Advisory Board (SAB) with four key appointments: Kenneth C. Anderson, MD, Hagop Kantarjian, MD, Raymond Schinazi, PhD, DSc, and Cameron Turtle, MBBS, PhD. Drs. Anderson, Kantarjian,

Science Translational Medicine Publishes First-in-Human Clinical Data and Supporting Preclinical Data for SYNB1020, Synlogic’s Synthetic Biotic™ Medicine in Development as a Potential Treatment for Hyperammonemia

From Startup Synlogic Tx Link to Full Article: –Phase 1 clinical trial to evaluate safety and tolerability of SYNB1020 in healthy volunteers demonstrated safety, clearance and proof of mechanism– – Data from ongoing Phase 1b/2a clinical trial in patients with cirrhosis and elevated ammonia expected mid-2019 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan.

Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

From Startup Aptinyx Link to Full Article: NYX-2925 did not achieve statistically significant separation from placebo on primary endpoint Meaningful improvements on pain and other endpoints observed in subjects receiving 50 mg dose and in subjects not taking a concomitant analgesic medication NYX-2925 was well-tolerated with no significant adverse

BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA

From Startup Brainstorm Cell Therapeutics Link to Full Article: Dr. Ralph Kern to Provide Update on the Phase 3 Pivotal Trial of Autologous MSC-NTF Cellular Therapy (NurOwn®) in ALS   NEW YORK and IRVINE, Calif., Jan. 11, 2019 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in

Led by Philips, Prenatal App Babyscripts Nabs $6M to Support Holistic Care for Mothers

From Startup BabyScripts Link to Full Article: Babyscripts, Inc., a Washington D.C.-based virtual care platform for managing obstetrics, announced today that Philips has taken a minority position in the company by leading a $6 million round of financing. The round also included participation from investors StartUp Health and NueCura Partners.

Basilea Announces Positive Interim Results from Registrational Phase 2 Study with Oncology Drug Candidate Derazantinib in Intrahepatic Cholangiocarcinoma (iCCA)

From Startup ARQULE Link to Full Article: 21% objective response rate with six confirmed partial responses from 29 evaluable patients 83% disease control rate Safety profile and tolerability of continuous dosing schedule confirmed BURLINGTON, Mass.–(BUSINESS WIRE)–Jan. 9, 2019– ArQule, Inc.’s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), today announced results

Genevant Appoints Dr. Margrit Schwarz as Chief Scientific Officer and Head of R&D, and Pete Zorn as Chief Operating Officer

From Startup Genevant Link to Full Article: Additions bolster Genevant’s leadership position in the RNA therapeutics space with its multiple modality, “pan-RNA” approach BOSTON, MASSACHUSETTS; BURNABY, CANADA; and BASEL, SWITZERLAND – January 7, 2019 – Genevant Sciences, a leading biopharmaceutical company focused on the discovery and development of a

Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises

From Startup Heron Therapeutics Link to Full Article: SAN DIEGO, Jan. 7, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today highlighted progress in its

AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors

From Startup Avrobio Link to Full Article: Industry leader brings global expertise, including as Shire’s former Global Head of Research and Development, to help further accelerate momentum and growth CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) — AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a clinical-stage gene therapy company, today announced